Arcadia Biosciences, Inc. (RKDA)
NASDAQ: RKDA · Real-Time Price · USD
3.915
+0.095 (2.49%)
Nov 4, 2024, 4:00 PM EST - Market closed
Arcadia Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 5.24 | 5.33 | 7.42 | 6.78 | 8.03 | 1.17 | Upgrade
|
| Revenue Growth (YoY) | 11.74% | -28.15% | 9.41% | -15.61% | 587.25% | -20.15% | Upgrade
|
| Cost of Revenue | 4.15 | 4.24 | 6.51 | 9 | 8.85 | 7.68 | Upgrade
|
| Gross Profit | 1.1 | 1.09 | 0.91 | -2.22 | -0.81 | -6.51 | Upgrade
|
| Selling, General & Admin | 14.58 | 14.51 | 15.04 | 22.09 | 16.4 | 13.57 | Upgrade
|
| Operating Expenses | 14.58 | 14.51 | 15.04 | 22.09 | 16.4 | 13.57 | Upgrade
|
| Operating Income | -13.48 | -13.42 | -14.13 | -24.31 | -17.21 | -20.08 | Upgrade
|
| Interest Expense | - | - | - | -0.02 | -0.05 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.49 | 0.7 | 0.29 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.53 | 0.09 | 2.9 | 8.07 | 6.61 | -9.67 | Upgrade
|
| EBT Excluding Unusual Items | -11.47 | -12.64 | -10.93 | -16.26 | -10.65 | -29.75 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -0.85 | -0.07 | - | Upgrade
|
| Impairment of Goodwill | - | - | - | -1.65 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 1.14 | 10.22 | 9.51 | 0.18 | Upgrade
|
| Gain (Loss) on Sale of Assets | 4.04 | 0.04 | 0.31 | -0.5 | - | - | Upgrade
|
| Asset Writedown | -0.59 | -0.56 | -1.4 | -8.43 | -4.31 | -0.3 | Upgrade
|
| Other Unusual Items | - | - | 0.07 | 1.33 | -0.64 | 1 | Upgrade
|
| Pretax Income | -8.02 | -13.16 | -10.81 | -16.13 | -6.15 | -28.87 | Upgrade
|
| Income Tax Expense | 0.01 | 0.01 | 0.01 | 0 | -0.12 | 0 | Upgrade
|
| Earnings From Continuing Operations | -8.03 | -13.17 | -10.83 | -16.13 | -6.03 | -28.87 | Upgrade
|
| Earnings From Discontinued Operations | 1.24 | -0.82 | -4.78 | - | - | - | Upgrade
|
| Net Income to Company | -6.78 | -13.99 | -15.61 | -16.13 | -6.03 | -28.87 | Upgrade
|
| Minority Interest in Earnings | - | 0.01 | 0.24 | 1.47 | 1.37 | 0.07 | Upgrade
|
| Net Income | -6.78 | -13.98 | -15.38 | -14.66 | -4.66 | -28.81 | Upgrade
|
| Net Income to Common | -6.78 | -13.98 | -15.38 | -14.66 | -4.66 | -28.81 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 55.17% | 106.37% | 12.66% | 113.68% | 56.51% | 68.94% | Upgrade
|
| EPS (Basic) | -4.98 | -11.30 | -25.65 | -27.56 | -18.70 | -181.07 | Upgrade
|
| EPS (Diluted) | -4.98 | -11.30 | -25.65 | -27.56 | -18.70 | -181.07 | Upgrade
|
| Free Cash Flow | -12.71 | -15.3 | -14.05 | -26.88 | -32.55 | -18.68 | Upgrade
|
| Free Cash Flow Per Share | -9.33 | -12.37 | -23.44 | -50.52 | -130.75 | -117.40 | Upgrade
|
| Gross Margin | 20.96% | 20.39% | 12.27% | -32.80% | -10.13% | - | Upgrade
|
| Operating Margin | -257.11% | -251.80% | -190.43% | -358.58% | -214.26% | -1717.45% | Upgrade
|
| Profit Margin | -129.33% | -262.31% | -207.28% | -216.22% | -57.94% | -2464.07% | Upgrade
|
| Free Cash Flow Margin | -242.41% | -287.04% | -189.39% | -396.39% | -405.19% | -1597.52% | Upgrade
|
| EBITDA | -13.25 | -13.13 | -13.65 | -23.27 | -16.55 | -19.88 | Upgrade
|
| EBITDA Margin | -252.65% | -246.42% | -183.97% | - | -206.02% | - | Upgrade
|
| D&A For EBITDA | 0.23 | 0.29 | 0.48 | 1.05 | 0.66 | 0.19 | Upgrade
|
| EBIT | -13.48 | -13.42 | -14.13 | -24.31 | -17.21 | -20.08 | Upgrade
|
| EBIT Margin | -257.11% | -251.80% | -190.43% | - | -214.26% | - | Upgrade
|
| Revenue as Reported | 5.24 | 5.33 | 7.42 | 6.78 | 8.03 | 1.17 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.